嘉應制藥(002198.SZ):股東黃智勇、黃利兵擬協議轉讓5.03%股份予劉理彪
格隆匯11月2日丨嘉應制藥(002198.SZ)公佈,公司於2021年11月2日接到公司股東黃智勇、黃利兵的通知,二位股東與劉理彪於2021年11月2日簽署了《黃智勇、黃利兵與劉理彪關於廣東嘉應制藥股份有限公司股份轉讓協議》。
根據協議內容,二位股東擬通過協議轉讓方式,合計將其持有的公司2550.51萬股(佔公司總股本的5.03%,其中:黃智勇轉讓24,997,848股,佔總股本的4.93%;黃利兵轉讓507,248股,佔總股本的0.10%)無限售流通股份轉讓給劉理彪,轉讓價格為8.38元/股,轉讓股份價款總額為2.14億元。
本次股份轉讓前,黃智勇持有公司股份24,997,848股,佔公司總股本的4.93%;黃利兵持有公司股份707,248股,佔公司總股本的0.14%;劉理彪未持有公司股份。
本次股份轉讓後,黃智勇不再持有公司股份;黃利兵持有200,000股,佔公司總股本的0.04%;劉理彪持有公司股份25,505,096股,佔公司總股本的5.03%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.